Journal of Pharmacy Technology最新文献_第9页

Development of an Emergency Revisit Score for Patients With Drug-Related Problems. 药物相关问题患者紧急重访评分的发展

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-04-30 DOI: 10.1177/87551225211011731

Jesus Ruiz Ramos, Laura Gras-Martin, Ana María Juanes Borrego, Marta Blazquez-Andion, Mireia Puig Campmany, Maria Antonia Mangues-Bafalluy

{"title":"Development of an Emergency Revisit Score for Patients With Drug-Related Problems.","authors":"Jesus Ruiz Ramos, Laura Gras-Martin, Ana María Juanes Borrego, Marta Blazquez-Andion, Mireia Puig Campmany, Maria Antonia Mangues-Bafalluy","doi":"10.1177/87551225211011731","DOIUrl":"https://doi.org/10.1177/87551225211011731","url":null,"abstract":"Background: Drug-related problems (DRPs) are a frequent reason for emergency departments (EDs) visits. However, data about the risk factors associated with EDs revisits are limited. Objective: To develop and validate a predictive model indicating the risk factors associated with EDs revisit within 30 days of the first visit. Methods: A retrospective cohort study was conducted involving patients who attended an ED for DRPs related to cardiovascular drugs. A 30-day prediction model was created in a derivation cohort by logistic regression. An integer score proportional to the regression coefficient was assigned to the variables with P < .100 in the multivariate analysis. Results: 581 patients (mean age: 80.0 [12.6] years) were included, 133 (22.9%) revisited the ED within 30 days from discharge. Six factors (chronic kidney disease, chronic heart failure, visit to an ED in the preceding 3 months, high anticholinergic burden, DRPs associated with heparin, and safety-related DRPs) were identified as risk factors and combined into a final score, termed the DREAMER score. The model reached an area under the receiver operating curve values of 0.72 (95% confidence interval [CI] = 0.67-0.77) in the referral cohort and 0.71 (95% CI = 0.65-0.74) in the validation cohort (P = .273). Three risk categories were generated, with the following scores and estimated risks: low risk (0-8 points): 11.6%; intermediate risk (9-14 points): 21.3%; and high risk (>14 points): 41.2%. Conclusion and Relevance: The DREAMER score identifies patients at high risk for ED revisit within 30 days from the first visit for a DRPs, being a useful tool to prioritize interventions on discharge.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"171-177"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211011731","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Efficacy of Apixaban Following Bioprosthetic Valve Replacements: A Retrospective Evaluation. 阿哌沙班在生物瓣膜置换术后的安全性和有效性:回顾性评价。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-06-04 DOI: 10.1177/87551225211021596

Kellie Ball, Elizabeth W Covington

{"title":"Safety and Efficacy of Apixaban Following Bioprosthetic Valve Replacements: A Retrospective Evaluation.","authors":"Kellie Ball, Elizabeth W Covington","doi":"10.1177/87551225211021596","DOIUrl":"https://doi.org/10.1177/87551225211021596","url":null,"abstract":"Background: Data on the use of direct oral anticoagulants in the setting of bioprosthetic valve replacements is limited. Objective: The purpose of this study was to describe outcomes among patients who underwent a bioprosthetic valve replacement and were subsequently prescribed apixaban. Methods: A retrospective cohort study was completed for inpatients at a community hospital who were prescribed apixaban following a bioprosthetic valve replacement from 2015 to 2020. Endpoints assessed included incidence of all-cause readmission and emergency visits within 3 months following valvular surgery, incidence of mortality, and all-cause major and minor bleeding. A post hoc analysis was conducted comparing outcomes among patients who underwent mitral versus aortic valve replacement, as well as patients with and without atrial fibrillation. The study was deemed exempt by hospital and university institutional review boards. Results: A total of 54 patients were included for analysis. All-cause readmission or emergency visit occurred in 33% (n = 18) of patients and the mortality rate was 6% (n = 3). A minor bleeding event was reported in 6% (n = 3) of patients and a major bleeding event was reported in 2% (n = 1) of patients. A thrombotic event was reported in 2% (n = 1) of patients. Conclusion: Within this cohort of patients requiring anticoagulation following bioprosthetic valve replacement, apixaban was safe and well-tolerated. However, more prospective data are needed to further correlate the safety and efficacy of apixaban, particularly in the setting of mitral valve replacement.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"193-201"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211021596","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39602955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease. criszanlizumab用于预防镰状细胞病血管闭塞性疼痛危机。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-04-19 DOI: 10.1177/87551225211008460

Debra L Stevens, Meri Hix, Brooke L Gildon

{"title":"Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.","authors":"Debra L Stevens, Meri Hix, Brooke L Gildon","doi":"10.1177/87551225211008460","DOIUrl":"https://doi.org/10.1177/87551225211008460","url":null,"abstract":"Objective: To review the efficacy and safety of crizanlizumab (Adakveo) in the prevention of vaso-occlusive pain crises in sickle cell disease. Data Sources: An English-language literature search of PubMed, MEDLINE, and Ovid (1946 to January 2021) was completed using the terms crizanlizumab, SEG101, SelG1, and sickle cell disease. Manufacturer prescribing information, article bibliographies, and data from clinicaltrials.gov were incorporated in the reviewed data. Study Selection/Data Extraction: All studies registered on clinicaltrials.gov were incorporated in the reviewed data. Data Synthesis: Crizanlizumab is the first monoclonal antibody approved for sickle cell disease to reduce the frequency of vaso-occlusive crises. One phase 2 clinical trial and a post hoc analysis of the trial have been published. Relevance to Patient Care and Clinical Practice: Crizanlizumab is a monthly intravenous infusion approved by the Food and Drug Administration for patients with sickle cell disease 16 years of age and older to reduce the frequency of vaso-occlusive crises. Conclusion: Crizanlizumab appears to be an efficacious therapy for patients with sickle cell disease to reduce the frequency of vaso-occlusive crises. Concerns include drug cost and administration. Long-term benefits and risks have not been determined.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"209-215"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211008460","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature. 第二代抗精神病药作为辅助镇痛药的疗效和安全性:文献综述。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-04-19 DOI: 10.1177/87551225211004145

Belinda Coronado, Jacob Dunn, Michael A Veronin, Justin P Reinert

{"title":"Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature.","authors":"Belinda Coronado, Jacob Dunn, Michael A Veronin, Justin P Reinert","doi":"10.1177/87551225211004145","DOIUrl":"https://doi.org/10.1177/87551225211004145","url":null,"abstract":"Objective: To determine the efficacy and safety of second-generation antipsychotics (SGAs) as adjunctive analgesics. Data Sources: A comprehensive literature review was conducted between August 2020 and January 2021 on PubMed, Scopus, and ProQuest Central. Study Selection and Data Extraction: Keyword and Boolean phrase searches using the following terminology were conducted: \"Quetiapine\" OR \"Risperidone\" OR \"Olanzapine\" OR \"Ziprasidone\" AND \"Analgesia\" NOT \"Psychosis\" NOT \"Psych.\" Articles that involved human adult patients who received any of the SGAs mentioned in the searching filter with an opioid were included. Articles that described pediatrics, pregnant women, patients who received any of these agents for treatment of psychosis and articles that were not in English, or readily translatable to English, were excluded. Data Synthesis: Three articles were selected for inclusion in this review, with 2 articles detailing reports with olanzapine and 1 article describing a randomized, controlled trial with extended-release quetiapine. Both olanzapine and quetiapine were able to decrease pain scores on the numeric rating scale, indicating a reduction pain experienced, and additionally reduced opioid craving behavior in patients. Depression scores and quality-of-life indicators improved with quetiapine, though those metrics were not studied with olanzapine. Conclusions: Select SGAs, specifically extended-release quetiapine and olanzapine, may serve as an appropriate adjunctive analgesic choice in select patients. Further research is required in a clinical setting to determine the exact role of this drug class in pain management.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"202-208"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211004145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Assessing Pharmacists' Views and Barriers to Providing and Billing for Pharmacist-Provided Health Care Services. 评估药剂师的观点和障碍提供和收费的药剂师提供的卫生保健服务。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-06-04 DOI: 10.1177/87551225211021187

Michael A Biddle, Kailyn K Cleveland, Shanna K O'Connor, Hayli Hruza, Madeline Foster, Elaine Nguyen, Renee Robinson, Thomas Wadsworth

{"title":"Assessing Pharmacists' Views and Barriers to Providing and Billing for Pharmacist-Provided Health Care Services.","authors":"Michael A Biddle, Kailyn K Cleveland, Shanna K O'Connor, Hayli Hruza, Madeline Foster, Elaine Nguyen, Renee Robinson, Thomas Wadsworth","doi":"10.1177/87551225211021187","DOIUrl":"https://doi.org/10.1177/87551225211021187","url":null,"abstract":"Background: The role of Idaho and Alaska pharmacists in providing health care services has steadily broadened over recent years. With many new pharmacist-provided health care service possibilities, this study assessed the impact of these advancements on community pharmacies. Objective: The objective of this study was to identify current pharmacist-provided health care services and pharmacist-perceived barriers to providing and billing for these services in Idaho and Alaska community pharmacies. Methods: A questionnaire was developed focusing on 2 areas: providing services and billing for services. Pharmacy students on experiential rotations administered the questionnaires to pharmacists at their rotation sites. Pharmacists at community pharmacy practice sites in Idaho and Alaska completed the questionnaire in an interview format conducted by students. Likert-type scale data were analyzed using descriptive statistics. Because the study did not include a comparator group, no power calculation was conducted. All open-response answers were analyzed independently by 2 researchers and discrepancies in coding open-ended questions were resolved by discussion with a group of 4 researchers. Results: Most pharmacists reported that they already provide non-dispensing services, desired to implement new services, and had confidence in their team's ability to handle new services. Time and resources were the most cited barriers to providing new services; compensation, company support, and education were the most cited barriers to billing for services. Conclusions: Community pharmacists already provide non-dispensing services and many are looking to provide more services, but barriers of time, resources, compensation, company support, and education will need to be overcome to move forward.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"186-192"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211021187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Reflections of pharmacy students on experiential education in providing health services to people with history of substance use disorders in Malaysia 马来西亚药学专业学生对为有药物使用障碍史的人提供保健服务的体验式教育的思考

IF 1

Journal of Pharmacy Technology Pub Date : 2021-07-31 DOI: 10.31436/JOP.V1I2.31

Nor Hidayah Mohd Taufek, Syafiqah Nadiah Halimi, Norny Syafinaz Ab Rahman, C. S. Zin, C. J. Turner

{"title":"Reflections of pharmacy students on experiential education in providing health services to people with history of substance use disorders in Malaysia","authors":"Nor Hidayah Mohd Taufek, Syafiqah Nadiah Halimi, Norny Syafinaz Ab Rahman, C. S. Zin, C. J. Turner","doi":"10.31436/JOP.V1I2.31","DOIUrl":"https://doi.org/10.31436/JOP.V1I2.31","url":null,"abstract":"Introduction: Accreditation standards for pharmacy students’ education include the requirement for experiential education (EE) and acknowledge, in building life-long learning skills, the need to develop students’ skills in analysing their practice-based performance. The goal of this qualitative study was to assess students’ ability to reflect on their experience providing face-to-face care to patients with a history of substance use disorders (PHSUDs).\u0000Materials and methods: Interviews were conducted with undergraduate pharmacy students who provided care to PHSUDs in an EE programme. An interview guide was used to explore students’ experiences and their perceptions regarding the challenges they encountered, changes in their attitude towards PHSUDs and ways to improve their ability to care for PHSUDs. Data relevant to the study was extracted from interview transcripts, manually sorted and coded using Microsoft Excel and subjected to thematic analysis. \u0000Results: The themes identified were 1) Increased self-confidence in face-to-face interactions with PHSUDs 2) Increased empathy towards PHSUDS 3) Reduction in stigmatised attitudes towards PHSUDs 4) Positive nature of the interactions with PHSUDs 5) Appreciation for the opportunity to apply knowledge in practice 6) Recognition of the need for improved communication skill training 7) Recognition of the need to improve training for dealing with unexpected questions and situations.\u0000Conclusion: Pharmacy students demonstrated reflective skills in identifying multiple positive learning outcomes stemming from a one-day EE programme involving PHSUDs. In addition, they provided insights useful to faculty in curriculum planning.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"70 8","pages":""},"PeriodicalIF":1.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72466525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perception towards Insulin Therapy and Factors Related to Insulin Refusal among Insulin Naive Type 2 Diabetes Mellitus Patients in Primary Care Clinics PKD Lipis 初级保健诊所首次使用胰岛素的2型糖尿病患者对胰岛素治疗的认知及胰岛素拒绝的相关因素

IF 1

Journal of Pharmacy Technology Pub Date : 2021-07-31 DOI: 10.31436/JOP.V1I2.52

N. Zakaria, Narasimman Baskaran, Wan Lin Lim

{"title":"Perception towards Insulin Therapy and Factors Related to Insulin Refusal among Insulin Naive Type 2 Diabetes Mellitus Patients in Primary Care Clinics PKD Lipis","authors":"N. Zakaria, Narasimman Baskaran, Wan Lin Lim","doi":"10.31436/JOP.V1I2.52","DOIUrl":"https://doi.org/10.31436/JOP.V1I2.52","url":null,"abstract":"Introduction: Insulin is one of the suggested treatments to prevent and reduce long-term diabetes complications. However, due to many factors such as socio-demographic factors, many Type 2 diabetes mellitus patients refuse this treatment. This study aimed to determine perception towards insulin among naive Type 2 diabetes mellitus patients, to calculate the prevalence of rejecting insulin therapy, and to find out factors related to the refusal.\u0000Materials and methods: This cross-sectional study involved 188 insulin naive Type 2 diabetes mellitus patients attending five primary health clinics in Lipis district, Pahang from October to November 2017. A five-point Likert Scale was used to determine perception towards insulin therapy and the Chi-square test was used to assess the proportion of acceptance of the therapy. Simple and multiple logistic regressions were utilised to study the associated factor(s).\u0000Results: Mean score of 60.5 ± 8.2 pointed towards a negative appraisal of insulin therapy. Embarrassment to inject in public (69.1%) and concern of frequent hypoglycaemia (52.7%) were the most common perception. Nearly half of the respondents (46.3%) refused insulin therapy upon suggestion. After adjusting the variables using multiple logistic regressions, only gender (Adjusted OR=0.20, 95% CI=0.10-0.40, p<0.001), educational level (Adjusted OR=0.17, 95% CI=0.06-0.50, p=0.001), age (Adjusted OR=1.04, 95% CI=1.01-1.08, p=0.012) and glycated haemoglobin level (Adjusted OR=1.33, 95% CI=1.07-1.67, p=0.013) remained significant.\u0000Conclusion: In conclusion, insulin refusal among insulin naive patients was common in Lipis with an overall negative perception towards therapy. By tailoring strategies according to the patient’s factors such as gender, educational level, age, and glycated haemoglobin level, the insulin refusal rate might decrease in the future.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"9 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74719166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature. 糖皮质激素治疗社区获得性肺炎:当前文献综述。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-06-01 Epub Date: 2021-02-22 DOI: 10.1177/8755122521995587

Lindsay K Harris, Andrew J Crannage

{"title":"Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature.","authors":"Lindsay K Harris, Andrew J Crannage","doi":"10.1177/8755122521995587","DOIUrl":"https://doi.org/10.1177/8755122521995587","url":null,"abstract":"Objective: To review the evidence and recommendations for the use of adjunctive corticosteroid therapy in community-acquired pneumonia (CAP). Data Sources: A literature search was conducted using PubMed (1993 to November 2020) using the search terms corticosteroids AND community-acquired pneumonia. Study Selection and Data Extraction: Pertinent randomized controlled trials, systematic reviews, and meta-analyses assessing the efficacy and safety of adjunctive corticosteroids in patients with pneumonia were evaluated for inclusion. Data Synthesis: Studies suggest that corticosteroids reduce time to clinical stability and length of hospital stay, but data regarding other important clinical outcomes, such as mortality, are limited. The greatest margin of benefit appears to be in patients with severe CAP. Evidence consistently demonstrates hyperglycemia as the most common adverse effect of corticosteroid therapy in CAP. Safety concerns regarding the potential impact of corticosteroids on the rate of CAP-related rehospitalizations require further investigation. Relevance to Patient Care and Clinical Practice: This review summarizes literature evaluating the efficacy and safety of adjunctive corticosteroids in patients with CAP. It also includes a discussion on current guideline recommendations, patient selection, corticosteroid regimens, adverse effect considerations, limitations, and future directions in this area of research. Conclusions: Studies reviewed suggest that corticosteroids are relatively beneficial and safe in patients with CAP, with the greatest benefit in severe CAP. Currently, the routine use of corticosteroids is not recommended by clinical practice guidelines with the exception of CAP and refractory septic shock. Further research is needed to better define the ideal role of corticosteroids in CAP.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 3","pages":"152-160"},"PeriodicalIF":1.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/8755122521995587","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39870188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature. 阿哌沙班用于腹膜透析的安全性和有效性:文献综述。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-06-01 Epub Date: 2021-01-20 DOI: 10.1177/8755122520988728

Armaghan Amani, Caitlin M Fellers, Antoinette Eyebe, Alyssa Hall, Meredith L Howard

{"title":"Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature.","authors":"Armaghan Amani, Caitlin M Fellers, Antoinette Eyebe, Alyssa Hall, Meredith L Howard","doi":"10.1177/8755122520988728","DOIUrl":"https://doi.org/10.1177/8755122520988728","url":null,"abstract":"Objective: To review the safety and efficacy of apixaban for the treatment of nonvalvular atrial fibrillation or venous thromboembolism in patients receiving peritoneal dialysis (PD). Data Sources: A PubMed and MEDLINE search was conducted through December 2020 using the following keywords and Medical Subject Headings (MeSH) terms alone or in various combinations: apixaban, peritoneal dialysis, continuous ambulatory peritoneal dialysis, end-stage renal disease, and hemodialysis. Study Selection and Data Extraction: English-language studies evaluating clinical outcomes pertaining to the use of apixaban in end stage renal disease (ESRD), which included patients receiving peritoneal dialysis were eligible for inclusion. Data Synthesis: Four studies were identified that met inclusion for this review, all retrospective in nature. These studies compared the safety and efficacy of apixaban with standard therapy in ESRD included patients on dialysis, with a very limited number of subjects receiving PD. In these studies, apixaban was shown to be potentially safer and more effective than warfarin. Outcomes did not differentiate between patients receiving PD or not. Conclusions: Use of apixaban in patients receiving PD may be safe and effective based on data from limited patients. Pharmacokinetics and pharmacodynamics of apixaban in the PD setting is an important question that clinicians should consider with use of this medication in the ESRD population. More studies focusing on the PD population are needed to better assess the use of apixaban in this understudied population.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 3","pages":"147-151"},"PeriodicalIF":1.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/8755122520988728","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39710348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Could Digital Image Prescriptions Enhance Patient Care? 数字图像处方能提高病人的护理水平吗?

IF 1

Journal of Pharmacy Technology Pub Date : 2021-06-01 Epub Date: 2021-01-05 DOI: 10.1177/8755122520982286

Alex Adams

引用次数: 0